Elevation Oncology Raises $65 M to Repurpose Failed Drug for Genomically Defined Tumors
In a bid to push Merrimack’s dropout drug seribantumab through Phase 2, Elevation Oncology has raised $65 M in a Series B financing round, led by new investors venBio Partners …
Read More